에볼라 출혈열과 말라리아와 같은 감염의 유행 증가와 일반 시민들 사이의 의식 증가와 같은 요인은 세계의 항감염제 시장의 성장을 가속하는 요인의 일부입니다. Verified Market Research의 애널리스트에 따르면 항감염제 시장은 2023년 1,397억 5,000만 달러의 수익을 밑도는 것으로 평가되었고, 2031년까지 1,780억 1,000만 달러의 평가에 이를 것으로 추정되고 있습니다.
세계적으로 고령 인구가 증가함에 따라 감염증에 대한 감수성이 높아지기 때문에 항감염제와 같은 의약품 수요가 급증합니다. 이 수요의 급증으로 시장은 2024년부터 2031년까지 CAGR 2.02%로 성장할 전망입니다.
항감염제 시장 정의 및 개요
항감염제란 세균, 바이러스, 진균, 기생충 등 다양한 병원체에 의한 감염증의 예방, 치료, 대책에 사용되는 약제나 물질의 폭넓은 카테고리를 가리킵니다. 이들 약제에는 항생제, 항바이러스제, 항진균제, 항균제, 백신 및 면역요법 등 다양한 의약품이 포함됩니다. 항감염제의 주요 작용은 감염균의 증식을 억제 또는 사멸시켜 감염병을 제어 또는 근절하고 감염자의 건강을 회복시키는 것입니다. 항감염제는 감염병을 관리하고 감염병 발생을 예방하며 지역사회 병원체의 만연을 억제함으로써 현대의학과 공중보건에서 중요한 역할을 하고 있습니다.
항감염제는 감염된 유기체를 완전히 죽일 수 있습니다. 항감염제 그룹은 항진균제, 구충제, 항말라리아제, 항결핵제, 항바이러스제, 항기생충제로 구성되어 있습니다. 식품의약국(FDA)은, HIV-1 감염 치료약의 데스코비나, 성인의 만성 C형 간염 바이러스(HCV) 제노 타입 1 또는 4 감염을 대상으로 하는 제파치 등, 다양한 종류의 의약품을 승인하고 있습니다.
세균 감염, 바이러스 감염, 진균 감염, 기생충 감염 등의 감염증이 세계적으로 증가하고, 항감염제 수요가 높아지고 있습니다. 인구증가, 도시화, 여행, 기후변화 등의 요인이 감염병 만연에 기여하고 있어 감염 확산을 억제하기 위해서는 효과적인 치료가 필요합니다. 일반적으로 항균제내성(AMR)으로 알려진 약제내성 병원체의 출현은 세계 공중위생에 큰 위협을 초래하고 있습니다. 현재의 치료법으로는 세균, 바이러스, 진균, 기생충의 내성주에 대처할 수 없기 때문에 내성 기전을 극복하고 다제내성 감염과 싸울 수 있는 신규하고 혁신적인 항감염제의 필요성이 높아지고 있어 항감염제 시장의 성장을 뒷받침하고 있습니다. 그 결과, 코로나19, HIV/AIDS, 뎅기열이나 말라리아와 같은 매개 감염병과 같은 감염병의 출현과 재출현은 그들과 싸우기 위한 효과적인 항감염제의 개발과 이용 가능성을 필요로 하고 있습니다.
수술, 이식, 면역억제 요법 등 치료와 처치가 복잡해짐에 따라 치료 관련 감염(HAI)의 위험이 높아지고 있습니다. 따라서 항감염제는 HAI 예방과 치료, 합병증의 발생률 저하, 헬스케어에서 환자의 결과 개선에 중요한 역할을 담당하고 있습니다. 공중 위생의 대처, 교육 캠페인, 의식 향상 프로그램에서는, 백신 접종, 손 위생, 항균약 치료 등의 감염 예방 및 관리 대책의 중요성이 추진되고 있습니다. 이러한 대처에 의해, 감염증의 부담을 경감해 공중 위생을 지키기 위한 포괄적인 전략의 일환으로서 항균약의 사용이 촉진되고 있습니다.
또한 신흥 국가의 가처분 소득 증가와 정부 이니셔티브는 건강 관리 지출 증가로 이어져 항감염제 수요 증가로 이어질 수 있습니다. 마찬가지로, 창약, 유전체학, 병용 요법, 개별화 의료에의 투자의 증가는, 부작용이 적은, 보다 표적을 좁힌 효과적인 항감염제의 개발로 이어지고 있습니다.
항감염제 시장에서 가장 중요한 과제 중 하나는 항균제에 내성을 가진 병원체의 출현과 만연입니다. 항생제, 항바이러스제, 항진균제, 항기생충제의 과도한 사용 및 남용은 약제 내성주의 출현의 한 원인이 되며, 새로운 항감염제의 긴급한 필요성에도 불구하고 기존 치료법의 효과를 저하시키고 감염병의 치료를 제한하고 있습니다. 항균제 개발 파이프라인은 비교적 적습니다. 많은 제약사들이 항균제에 대한 투자를 줄이고 있는 것은 이들 치료법의 비용이 높고 개발 기간이 길어 상업적 수익이 불확실하기 때문입니다. 그 결과 새로운 항생제나 기타 항감염제가 시장에 나오지 않아 항균제 내성 문제를 악화시키고 있습니다.
신규 항감염제의 규제 당국에 의한 승인 프로세스는 특히 약제의 경우 길고 복잡하며 자원이 필요합니다. 특히, 다제내성 병원체나 신흥 감염병을 대상으로 하는 약제는 승인까지 오랜 시간과 복잡한 노력을 필요로 합니다. 규제 당국은 안전성, 유효성, 약물 동태를 증명하는 광범위한 임상 데이터를 요구하는데, 특히 항균제의 유효성을 나타내는 대용물질이나 바이오마커가 정의되지 않은 경우 신규 치료제 승인이나 시장 진입이 지연될 수 있습니다. 가격 압력, 상환 관행, 시장 역학을 포함한 경제적 인사이트는 감염병 치료제를 개발 및 상품화하는 기업에 있어서 과제입니다. 제네릭 항생제의 저렴한 가격과 임상 개발 및 규제 준수를 위한 고비용이 제약사가 새로운 항균제, 특히 특정 적응증이나 소수의 환자 집단을 대상으로 하는 항균제에 투자하는 것을 방해하고 있습니다.
자원에 제약이 있는 환경, 특히 의료 인프라가 빈약한 중저소득 국가에서는 항감염제의 입수가 제한되는 경우가 많습니다. 또한 진단이나 치료의 선택지가 불충분한 경우도 있습니다. 항균제 비용이 많이 들고 의료 서비스 부족, 유통 및 공급망 관리 문제 등이 지역에서 효과적인 감염 치료에 대한 액세스를 더욱 방해합니다.
The rising prevalence of infectious diseases such as Ebola and malaria along with other factors such as growing awareness among the commoners are some of the factors that are driving the growth of the global anti-infective agents market. According to the analyst from Verified Market Research, the Anti-infective Agents Market is estimated to reach a valuation of USD 178.01 Billion by 2031 by subjugating the revenue of USD 139.75 Billion in 2023.
As the geriatric population grows globally, the requirement of medications like anti-infective agents spurs due to their higher susceptibility to infections. This surge in demand enables the market to grow at aCAGR of 2.02% from 2024 to 2031.
Anti-Infective Agents Market: Definition/ Overview
Anti-infective agents refer to a broad category of medications or substances used to prevent, treat, or combat infections caused by various pathogens, including bacteria, viruses, fungi, and parasites. These agents encompass a diverse range of pharmaceuticals, including antibiotics, antivirals, antifungals, and antiphrastic drugs, as well as vaccines and immunotherapies. Their primary function is to inhibit the growth or kill the infectious organisms, thereby controlling or eradicating the infection and restoring health to the affected individual. Anti-infective agents play a critical role in modern medicine and public health by helping to manage infectious diseases, prevent outbreaks, and reduce the spread of pathogens within communities.
The anti-infective agents can also kill the infectious organism outright. The anti-infective group consists of antifungals, anthelmintics, anthelmintics, antimalarials, antituberculosis agents, antivirals, and antiprotozoals. The Food and Drug Administration (FDA) approved various types of drugs such as Descovy for the treatment of HIV-1 infection and Zepatier that target the chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The global increase in infectious diseases, including bacterial, viral, fungal, and parasitic infections, is increasing the demand for anti-infective agents. Factors such as population growth, urbanization, travel, and climate change contribute to the spread of infectious diseases that require effective treatment to control the spread of infection. The emergence of drug-resistant pathogens, commonly known as antimicrobial resistance (AMR), poses a major threat to public health worldwide. As current treatments fail against resistant strains of bacteria, viruses, fungi, and parasites, there is a growing need for new and innovative anti-infective agents that can overcome resistance mechanisms and combat multidrug-resistant infections, thereby, boosting the growth of the anti-infective agents market. Consequently, the emergence and re-emergence of infectious diseases like COVID-19, HIV/AIDS, and vector-borne infections like dengue and malaria necessitate the development and availability of effective anti-infective agents to combat them.
The increasing complexity of medicine and procedures, including surgery, transplantation, and immunosuppressive therapy, increases the risk of treatment-associated infections (HAIs). Thus, anti-infective agents play an important role in preventing and treating HAIs, reducing the incidence of complications, and improving patient outcomes in healthcare. Public health initiatives, educational campaigns, and awareness programs promote the importance of infection prevention and control measures, including vaccination, hand hygiene, and antimicrobial treatment. These efforts promote the use of antimicrobial agents as part of comprehensive strategies to reduce the burden of infectious diseases and protect public health.
Also, growing disposable income and government initiatives in emerging countries are leading to rise in healthcare spending, potentially leading to higher demand for anti-infective agents. Similarly, rise in investment on drug discovery, genomics, combination therapies, and personalized medicine are leading to the development of more targeted and effective anti-infective agents with fewer side effects.
One of the most important challenges in the anti-infective market is the emergence and spread of pathogens resistant to antimicrobials. The excessive use and abuse of antibiotics, antivirals, antifungals, and anti-parasitic contribute to the emergence of drug-resistant strains, making existing treatments less effective and limiting treatment for infectious diseases despite the urgent need for new anti-infective agents, the pharmaceutical. The antimicrobial development pipeline is relatively small. Many pharmaceutical companies have reduced their investments in antimicrobial RandD drugs due to the high costs, long development timelines, and uncertain commercial returns of these therapies. As a result, there are no new antibiotics or other anti-infective agents on the market, exacerbating the problem of antimicrobial resistance.
Regulatory approval processes for new anti-infective agents can be long, complex, and resource intensive, especially for drugs. That targets multidrug-resistant pathogens or emerging infectious diseases. Regulatory agencies require extensive clinical data demonstrating safety, efficacy, and pharmacokinetics, which can delay approval and market entry of new therapies, particularly in the absence of defined surrogates or biomarkers of antimicrobial efficacy. Economic considerations, including pricing pressures, reimbursement practices, and market dynamics, present challenges to companies that develop and commercialize infectious agents. The low prices of generic antibiotics and the high costs of clinical development and regulatory compliance prevent pharmaceutical companies from investing in new antimicrobials, especially those targeting specific indications or small patient populations.
Availability of anti-infectives is often limited in resource-constrained settings, especially in low and middle-income countries with poor health infrastructure. , diagnostic options, and treatment options may be inadequate. The high cost of proprietary antimicrobials, lack of health services, and problems with distribution and supply chain management further impede access to effective infectious disease treatments in these regions.
The antibacterial segment is anticipated to hold almost 50% share in the anti-infective agents market. This dominance of antibacterial agents is primarily due to their increasing use to treat a broad spectrum of bacterial infections, right from common respiratory infections to life-threatening conditions like pneumonia and sepsis. In the majority of cases, bacterial infections are proven to be a common cause of illnesses, propelling demand for antibacterial agents for prevention and treatment.
Ongoing research and development in the field of antibacterial drug discovery or therapies along with the presence of prominent drug manufacturers developing new antibiotics to treat infections is projected to bolster the sales of antibacterial agents over the coming years. However, the rise of antimicrobial resistance is a growing concern, necessitating the development of novel anti-infective agents across all categories to combat various types of infections.
While the antibacterial segment is estimated to hold a major share of the market, the antiviral segment is anticipated to exhibit rapid growth over the forecast period after the emergence of the COVID-19 pandemic.
The oral administration is currently holding the leading position in the route of administration segment within the anti-infective agents market during the forecast period. The convenience for administration in patients compared to other routes, including injection or inhalation, is surging demand for oral administration. Also, the need for improved medical adherence and efficient treatment outcomes creates lucrative opportunities for oral medications.
Additionally, the cost-effectiveness is projected to increase its accessibility for patients and healthcare systems.
Besides, the availability of a vast array of anti-infective agents in oral formulations, catering to the treatment of various infections across different patient populations is a market growth booster.
Asia-Pacific has a huge and diversified population, resulting in differing degrees of healthcare access and infrastructure. The region has a high incidence of infectious illnesses, such as respiratory infections, diarrheal diseases, vector-borne diseases, and new infectious threats including antimicrobial-resistant infections. Infectious disorders are prevalent in the region, driving the demand for effective anti-infective medications. Many Asia-Pacific countries are experiencing economic growth and development, which is driving up healthcare spending and infrastructure investment. Rising affluence, urbanization, and government measures to promote healthcare access all contribute to increased demand for healthcare services, such as anti-infective medicines. Emerging economies in Asia-Pacific, including China, India, Indonesia, and Vietnam, provide considerable growth potential for pharmaceutical businesses and healthcare services.
This region has antimicrobial resistance (AMR) concerns as a result of extensive antibiotic usage, insufficient infection control measures, and restricted access to healthcare services. Addressing antimicrobial resistance necessitates collaborative efforts to encourage antimicrobial stewardship, surveillance, and research, resulting in an increased need for new and novel anti-infective drugs in the area. Governments in the Asia-Pacific region are launching steps to enhance healthcare systems, increase access to medications, and address public health concerns, especially infectious illnesses. Public-private collaborations, legislative changes, and investment incentives are all helping fund anti-infective agent research and development, promoting innovation and market expansion.
North American healthcare systems and infrastructure are among the most sophisticated in the world. The region is home to prominent pharmaceutical businesses, research organizations, and healthcare facilities focused on infectious disease management and treatment. The availability of cutting-edge medical facilities and experience helps to accelerate the research, manufacture, and uptake of anti-infective medications.
North American government is making large investments in pharmaceutical and healthcare research and development (R&D). The presence of prestigious academic institutions, government-funded research organizations, and private-sector R&D facilities accelerated the discovery and development of novel anti-infective agents. The region's powerful R&D environment helps scientists to translate their findings into clinically useful therapies. The regulatory framework in North America, notably in the United States, supports pharmaceutical discovery and commercialization.
Despite its modern healthcare system, North America continues to confront difficulties from infectious illnesses and antibiotic resistance. The region bears a heavy burden of healthcare-associated diseases, community-acquired illnesses, and new infectious threats. Antimicrobial resistance is becoming a major problem, demanding the development of new anti-infective medicines with novel modes of action and increased efficacy. Many of the world's largest pharmaceutical firms conduct research, development, production, and marketing of anti-infective drugs in North America. These firms use their scientific knowledge, financial resources, and worldwide networks to spur innovation and fulfill unmet medical needs in infectious disease treatment. The existence of a robust pharmaceutical industry ecosystem helps North America dominate the anti-infective agents market.
The competitive landscape in the anti-infective agents market is dynamic and evolving, driven by changing customer preferences, technological advancements, and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.
Some of the prominent players operating in the anti-infective agents market include:
Pfizer, Inc., Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc., Bayer Healthcare AG, AstraZeneca Plc., Boehringer Ingelheim, Novartis AG, Astellas Pharma, Inc., GlaxoSmithKline Plc., Alcon Pharmaceuticals Ltd.
In February 2024, a novel antifungal drug developed by Gilead Sciences, Inc. was approved by the FDA to treat an uncommon and potentially fatal fungal infection. Its repertoire of anti-infective medicines is expanded by this approval.
In August 2023, in order to treat respiratory syncytial virus (RSV) infection in newborns, Merck & Co., Inc. recently reported positive Phase 3 trial results for its experimental antiviral medication. There may be a new therapeutic option in this area thanks to this development.